Structure Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Structure Therapeutics Inc. reports significant progress in its obesity and metabolic disease pipeline, including positive Phase 2b data for aleniglipron and a $100 million non-exclusive license agreement.
NASDAQ
Structure Therapeutics Inc. announces its 2024 financial results and highlights progress in its clinical programs targeting obesity and idiopathic pulmonary fibrosis (IPF).
NASDAQ
Structure Therapeutics Inc.'s annual 10-K filing highlights advancements in their clinical programs, particularly for GSBR-1290, and strategic collaborations with Schrdinger.